GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » Retained Earnings

Tryptamine Therapeutics (ASX:TYP) Retained Earnings : A$-35.03 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Tryptamine Therapeutics's retained earnings for the quarter that ended in Dec. 2023 was A$-35.03 Mil.

Tryptamine Therapeutics's quarterly retained earnings declined from Dec. 2022 (A$-30.71 Mil) to Jun. 2023 (A$-33.42 Mil) and declined from Jun. 2023 (A$-33.42 Mil) to Dec. 2023 (A$-35.03 Mil).

Tryptamine Therapeutics's annual retained earnings declined from Jun. 2021 (A$-16.21 Mil) to Jun. 2022 (A$-26.29 Mil) and declined from Jun. 2022 (A$-26.29 Mil) to Jun. 2023 (A$-33.42 Mil).


Tryptamine Therapeutics Retained Earnings Historical Data

The historical data trend for Tryptamine Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics Retained Earnings Chart

Tryptamine Therapeutics Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Retained Earnings
Get a 7-Day Free Trial -2.46 -7.74 -16.21 -26.29 -33.42

Tryptamine Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -23.78 -26.29 -30.71 -33.42 -35.03

Tryptamine Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Tryptamine Therapeutics  (ASX:TYP) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Tryptamine Therapeutics (ASX:TYP) Business Description

Traded in Other Exchanges
N/A
Address
697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124
Exopharm Ltd is a biopharmaceutical company that engages in the development of regenerative medicine in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. The company operates in one segment namely the research and development of biopharmaceutical drugs. Revenue is generated from Australia.

Tryptamine Therapeutics (ASX:TYP) Headlines

No Headlines